Survival after high-dose chemotherapy for refractory and recurrent Ewing sarcoma

Area of Science:

• Pediatric Oncology
• Sarcoma Research
• Clinical Trial Analysis

Background:

• Primary refractory or recurrent Ewing sarcoma (RRES) presents a poor prognosis.
• The efficacy of high-dose therapy (HDT) in RRES remains uncertain.
• A retrospective review was conducted to evaluate RRES treatment outcomes.

Purpose of the Study:

• To assess the role of HDT in RRES.
• To develop a prognostic risk score for RRES patients.
• To improve clinical decision-making for RRES management.

Main Methods:

• Retrospective review of 196 RRES patients treated over 22 years.
• Comparison of outcomes between HDT, standard non-HDT chemotherapy, and no systemic therapy groups.
• Development of a prognostic index based on four significant multivariate factors.

Main Results:

• HDT was associated with superior overall survival (median 76 months) compared to non-HDT (median 10.5 months).
• Two-year post-relapse survival (PRS) was 67.9% for HDT versus 20.5% for non-HDT.
• A prognostic index stratified patients into good, intermediate, and poor prognosis groups, with higher scores linked to reduced PRS.

Conclusions:

• HDT demonstrates superior outcomes in RRES patients compared to non-HDT chemotherapy.
• A developed prognostic index allows for risk stratification of RRES patients.
• HDT benefits may extend to patients with poor prognostic scores.